Oruka Therapeutics, Inc. (ORKA)

NGM – Цена в реальном времени. Валюта: USD

64.65

-1.03 (-1.57%)

При закрытии: May 12, 2026, 4:00 PM EDT

64.11

-0.54 (-0.84%)

До открытия: May 13, 2026, 4:29 AM EDT

06.05.2026

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.

28.04.2026

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Oruka. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions.

27.04.2026

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

27.04.2026

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

27.04.2026

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001's half-life extension technology targets once-yearly dosing, aiming for best-in-class efficacy and competitive differentiation in a crowded biologics market. Key near-term catalysts include longer-term phase 2a follow-up data in H2 2026 and phase 2b EVERLAST-B dose-finding results in 2027 for ORKA-001.

27.04.2026

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis.

27.04.2026

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif.

Видео

No Data

There is no data to display

Пресс-релизы

06.05.2026

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

28.04.2026

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

27.04.2026

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

27.04.2026

Oruka Therapeutics, Inc. (ORKA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Oruka Therapeutics, Inc. (ORKA)

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Видео

No Data

Пресс-релизы

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Видео

No Data

Пресс-релизы

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Search stocks

Oruka Therapeutics, Inc. (ORKA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Oruka Therapeutics, Inc. (ORKA)

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Видео

No Data

Пресс-релизы

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Видео

No Data

Пресс-релизы

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis